Ocuphire Pharma (NASDAQ:OCUP – Get Rating)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Friday, TipRanks reports. They currently have a $26.00 price objective on the stock.
Separately, Zacks Investment Research raised shares of Ocuphire Pharma from a “sell” rating to a “hold” rating in a research report on Thursday.
NASDAQ:OCUP traded down $0.03 during trading hours on Friday, reaching $2.01. The company’s stock had a trading volume of 301,017 shares, compared to its average volume of 159,914. The company has a market cap of $38.91 million, a price-to-earnings ratio of -1.37 and a beta of 0.32. Ocuphire Pharma has a one year low of $1.80 and a one year high of $7.00. The business’s 50-day moving average is $2.82 and its 200-day moving average is $3.31.
Institutional investors and hedge funds have recently made changes to their positions in the company. Morgan Stanley raised its position in shares of Ocuphire Pharma by 779.4% during the first quarter. Morgan Stanley now owns 6,156 shares of the company’s stock valued at $36,000 after buying an additional 5,456 shares during the last quarter. Spire Wealth Management bought a new stake in Ocuphire Pharma in the first quarter valued at about $29,000. MCF Advisors LLC bought a new stake in Ocuphire Pharma in the first quarter valued at about $31,000. Squarepoint Ops LLC bought a new stake in Ocuphire Pharma in the fourth quarter valued at about $40,000. Finally, Powell Investment Advisors LLC bought a new stake in Ocuphire Pharma in the first quarter valued at about $44,000. 27.60% of the stock is owned by institutional investors and hedge funds.
Ocuphire Pharma Company Profile (Get Rating)
Ocuphire Pharma, Inc, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia.
- Get a free copy of the StockNews.com research report on Ocuphire Pharma (OCUP)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Ocuphire Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocuphire Pharma and related companies with MarketBeat.com's FREE daily email newsletter.